Patents/Inventors

John R Desjarlais

Pasadena, CAUS19 patents

20 Patents

US125595722026
Compositions and Methods for Treating Ige-mediated Disorders
Xencor, Inc.
0 cites
US124974572025
Methods and Compositions for Inhibiting CD32B Expressing Cells in Igg4-related Diseases
Xencor, Inc.
0 cites
US124922532025
Anti-human C5 Antibodies
Xencor, Inc.
0 cites
US124484232025
Targeted Heterodimeric Fc Fusion Proteins Containing NKG2D Antigen Binding Domains
Xencor, Inc.
0 cites
US124043292025
Heterodimeric Antibodies That Bind Prostate Specific Membrane Antigen (PSMA) and CD3
Xencor, Inc.
0 cites
US123982072025
Heterodimeric Antibodies That Bind CD3 and CLDN6
Xencor, Inc.
0 cites
US123783262025
Anti-cd28 X Anti-psma Antibodies
Xencor, Inc.
0 cites
US123657432025
Anti-cd28 X Anti-psma Antibodies
Xencor, Inc.
0 cites
US122342702025
IL-12 Heterodimeric Fc-fusion Proteins
Xencor, Inc.
0 cites
US122151652025
Fc Variants with Altered Binding to Fcrn
Xencor, Inc.
0 cites
US119326852024
Fc Variants with Altered Binding to Fcrn
XENCOR, Inc.
0 cites
US119199562024
Heterodimeric Antibodies That Bind Prostate Specific Membrane Antigen (PSMA) and CD3
Xencor, Inc.
0 cites
US119199582024
Anti-cd28 Compositions
Xencor, Inc.
0 cites
US118514662023
Targeted IL-12 Heterodimeric Fc-fusion Proteins
Xencor, Inc.
0 cites
US117391442023
Heterodimeric Antibodies That Bind CD3 and CLDN6
Xencor, Inc.
0 cites
US116552772023
IL-12 Heterodimeric Fc-fusion Proteins
Xencor, Inc.
0 cites
US116187762023
Targeted Heterodimeric Fc Fusion Proteins Containing IL-15/IL-15RA and NKG2D Antigen Binding Domains
Xencor, Inc.
0 cites
US116187882023
Optimized Antibodies That Target CD19
XENCOR, Inc.
0 cites
US115914012023
Anti-cd28 Compositions
Xencor, Inc.
0 cites
US115660802023
Compositions and Methods for Treating Ige-mediated Disorders
Xencor, Inc.
0 cites